Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB154 + Fluorouracil + Irinotecan + Leucovorin + Zimberelimab |
| Synonyms | FOLFIRI + Zimberelimab + Domvanalimab |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB154 | AB-154|AB 154|Domvanalimab | Immune Checkpoint Inhibitor 150 TIGIT Antibody 21 | AB154 (domvanalimab) is a monoclonal antibody that targets T-cell immunoreceptor with Ig and ITIM domains (TIGIT), potentially resulting in enhanced immune response (Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A124). | |
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
| Leucovorin | Wellcovorin | Calcium folinate|Calcium citrovorum factor|folinic acid | Chemotherapy - Antimetabolite 14 | Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (PMID: 32490554). |
| Zimberelimab | GLS-010|AB122|AB-122|GLS010 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 136 | Zimberelimab (GLS-010) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28679395). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07337447 | Phase II | Fluorouracil + Irinotecan + Leucovorin AB154 + Fluorouracil + Irinotecan + Leucovorin + Zimberelimab | Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) (REWENEC 01) | Not yet recruiting | FRA | 0 |